Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters
Growth Seen In First Full Quarter With Dual Migraine Indications
The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.
You may also be interested in...
As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.
Q3 results show Austedo appears headed towards blockbuster status, and the company signed a collaboration with MODAG for two compounds for neurodegenerative diseases.
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.